RxDoctor Payments Data

Kinnari Kennedy

Urology · Leesburg, VANPI 1952763435

Payments from drug & device makers

$4,953in general payments, 2019–2025

Across 185 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Medtronic$1K
  • Sumitomo Pharma America, Inc.$347
  • Johnson & Johnson$285
  • Coloplast$261
  • AbbVie$192
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$4569%
  • Food & beverage$4,34288%
  • Education$1553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,953 in reported general payments places this provider in the 60th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$182,486
Medicare patients
542
Services billed
3,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron154$109,624
GemtesaVibegron102$73,592
Methenamine Hippurate90$9,070
Estradiol74$4,866
Tamsulosin Hcl234$3,637
Solifenacin Succinate44$2,377
Trospium Chloride ErTrospium Chloride16$1,845
Finasteride77$990
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst55$782
Oxybutynin Chloride ErOxybutynin Chloride22$668
Cefpodoxime Proxetil11$422
Oxybutynin Chloride29$176
Hydroxyzine Hcl21$137
Ciprofloxacin Hcl36$135
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$177$109,624154 claims
Sumitomo Pharma America, Inc.Gemtesa$347$73,592102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 300 urology providers in Virginia.

Other urology in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →